ERBB2 and breast cancer: In the context of HER2-amplified breast cancer, either TBX3 loss-of-function or SIRT6 amplification predicts a worse survival than patients with no alterations in SIRT6 and TBX3 (Fig. 8H, Log-rank P = 0.0007).